BBIO ▲ +0.4% - BridgeBio Pharma, Inc. $BBIO - Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening BridgeBio Pharma rose 0.4% today following announcement that its drug acoramidis showed superior real-world outcomes compared to competitor tafamidis in treating transthyretin cardiac amyloidosis (ATTR-CM), with data demonstrating a reduced risk of clinical worsening. The positive efficacy comparison against the established standard of care supports the competitive positioning of acoramidis in this patient population. 23-SEP-2026 07:47 AM ET